Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Depreciation & Amortization (CF) of $29000.0 in Q1 2026, up 11.54% quarter-over-quarter from $26000.0 in Q4 2025, and up 31.82% on a YoY basis from $22000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $29000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 31.82% year-over-year to $29000.0; the TTM figure through Mar 2026 stood at $112000.0 (up 33.33% YoY), while the FY2025 annual figure was $105000.0, up 23.53% from the prior year.
- Depreciation & Amortization (CF) was $29000.0 for Q1 2026 at Corvus Pharmaceuticals, up from $26000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $94000.0 in Q3 2022 to a low of $20000.0 in Q4 2024.
- Historically, Depreciation & Amortization (CF) has averaged $43352.9 across 5 years, with a median of $29000.0 in 2025.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) tumbled 70.21% in 2023, then soared 38.1% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $94000.0 in 2022, then sank by 70.21% to $28000.0 in 2023, then decreased by 28.57% to $20000.0 in 2024, then rose by 30.0% to $26000.0 in 2025, then climbed by 11.54% to $29000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $29000.0 (Q1 2026), $26000.0 (Q4 2025), and $28000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - | 29,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 26,000.00 |
| Dec 31, 2025 | 26,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Dec 31, 2024 | 20,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Sep 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Dec 31, 2023 | 28,000.00 |
| Dec 31, 2023 | 28,000.00 |